Send us Feedback

MediciNova (MNOV)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

MNOV » Topics » ITEM 5. OTHER INFORMATION.

This excerpt taken from the MNOV 10-Q filed Aug 9, 2006.

ITEM 5. OTHER INFORMATION.

None.

 

ITEM 6. EXHIBITS.

 

Exhibit
Number		   

Description

31.1    Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2    Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1    Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002).
32.2    Certification of Principal Accounting Officer pursuant to 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002).

 

36

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    MEDICINOVA, INC.

Date: August 9, 2006

    

By:

   /s/    YUICHI IWAKI        
       

Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer and Acting Chief Financial Officer (on behalf of the registrant and as the registrant’s Principal Executive Officer and

Principal Financial Officer)

 

37

INDEX TO EXHIBITS

 

Exhibit
Number		   

Description

31.1    Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2    Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1    Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002).
32.2    Certification of Principal Accounting Officer pursuant to 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002).

 

38

This excerpt taken from the MNOV 10-Q filed May 12, 2005.

ITEM 5. OTHER INFORMATION.

 

Effective May 2, 2005, we promoted Brian Anderson from Executive Vice President, Corporate Development to Chief Business Officer and promoted Richard E. Gammans from Executive Vice President, Clinical Research to Chief Development Officer. In addition, effective May 2, 2005, the employment of Mark Lotz, Vice President, Regulatory Affairs was terminated.

 

EXCERPTS ON THIS PAGE:

10-Q
Aug 9, 2006
10-Q
May 12, 2005

RELATED TOPICS for MNOV:

"ITEM 5. OTHER INFORMATION." elsewhere:

ARIAD Pharmaceuticals (ARIA)
Corcept Therapeutics (CORT)
Cyclacel Pharmaceuticals (CYCC)
EXACT Sciences (EXAS)
Genta (GNTA)
GenVec (GNVC)
Inhibitex (INHX)
Osiris Therapeutics (OSIR)
Panacos Pharmaceuticals (PANC)
Sunesis Pharmaceuticals (SNSS)
Senesco Technologies (SNT)
AmpliPhi Biosciences Corp (TGEN)
Theravance (THRX)
Vical (VICL)
XenoPort (XNPT)
ZIOPHARM ONCOLOGY (ZIOP)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki